title: Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?
authors: Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
authors: Toyokawa
authors: T
authors: Gouji
authors: Seto
authors: S
authors: Takashi
authors: Takenoyama
authors: T
authors: Mitsuhiro
authors: Ichinose
authors: I
authors: Yukito
mesh_terms: D002227:Carbazoles / Q000494:pharmacology*; D000077547:Crizotinib; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics; D005784:Gene Amplification; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D010880:Piperidines / Q000494:pharmacology*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*
chemical_list: D002227:Carbazoles; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; C582670:alectinib